The main goal of NEXT GEN CART MAD-CM is to develop a new generation of cell engineering tools applicable to adoptive cellular immunotherapies that offer real clinical solutions for the treatment of refractory neoplasms, identify chemical or biological modulators to expand the therapeutic window of CAR-T cells, improve their antitumor activity and develop specific tools for disease and treatment monitoring.

  • There are currently three clinical trials already approved for members of this consortium (HNJS and UAM/HULP). These studies will provide critical information on treatment development using the most advanced genomic and molecular techniques, including single cell sequencing of both scRNA-seq and scATAC-seq and the development of protein microchips for real-time detection of specific biomarkers of treatment development that can be applied to clinical practice.
  • In addition, small organic molecules (small chemicals) with the capacity to inhibit CAR-T cell senescence will be identified in order to expand the therapeutic window of these treatments.
  • We will develop new cell engineering tools applied to immune system cells: a) New CAR and STAb vectors directed against poor prognosis, refractory and pediatric tumors; and b) Tumor-restricted interleukin inducible expression vectors to generate 4th generation CAR-T and CAR-NK that can be used in conjunction with the new CAR vectors generated in this consortium.
  • The therapeutic effect of these new vectors and of multi-target combinations of vectors (a) and (b), together with their combination with Celyvir virotherapy, will undergo extensive preclinical validation. The most promising results will be validated in at least two “firstin human” clinical trials in patients with refractory cancer in Madrid.
  • As a consequence of all the results obtained, we want to establish this consortium as a national and international reference in the development and clinical application of adoptive cellular immunotherapies.